Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Shares Outstanding (Diluted Average) (2022 - 2025)

Regen BioPharma (RGBP) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $20.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 383.09% to $20.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $20.4 million, a 383.09% increase, with the full-year FY2024 number at $4.1 million, up 16.21% from a year prior.
  • Shares Outstanding (Diluted Average) was $20.4 million for Q2 2025 at Regen BioPharma, up from $18.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $20.4 million in Q2 2025 to a low of $3.1 million in Q3 2022.
  • A 4-year average of $6.6 million and a median of $4.1 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 7.01% in 2023, then skyrocketed 383.09% in 2025.
  • Regen BioPharma's Shares Outstanding (Diluted Average) stood at $3.4 million in 2022, then rose by 7.01% to $3.6 million in 2023, then grew by 14.3% to $4.1 million in 2024, then soared by 395.23% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Shares Outstanding (Diluted Average) are $20.4 million (Q2 2025), $18.7 million (Q1 2025), and $4.1 million (Q4 2024).